Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield NC Non‑Formulary Prior Auth…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Non-Formulary Exception Criteria for Approval

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the clinical and documentation requirements for approval of non-formulary drug exceptions for Medicare Part D members, including required trials of formulary alternatives and acceptable prescriber rationale.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyNon-Formulary Exception Criteria for Approval
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Last ReviewJan 1, 2025
    Next Review DateJan 1, 2025
    Key ActionObtain prior authorization with documentation showing trial and failure or intolerance of at least three formulary alternatives (or prescriber justification why alternatives are unsuitable).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3required alternative formulary medications tried
    12length of approval (months)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medicare Part D
    program applicability

    Non‑Formulary Exception Coverage Criteria

    Non-Formulary Exception Approval Criteria

    Covered when ONE of the following is met

    Primary criteria: The member has tried at least three alternative formulary medications that have a similar mechanism of action as the requested medication AND the member either did not respond to or did not tolerate the formulary alternative medications. If three medications with a similar mechanism of action are not available on formulary, the member has tried three alternative formulary medications that are medically acceptable to treat the member’s condition. NOTE: If the requested medication is a multi-source brand and the generic equivalent is covered on the formulary, the member must have tried and failed the generic medication equivalent as one of the three required formulary alternatives.3 failed or intolerant formulary alternatives

    Length of approval: 12 months

    Alternative prescriber rationale: The prescriber provides an explanation of why formulary alternative medications would not be as effective in treating the member’s condition and/or would cause the member to have adverse effects.documented prescriber justification

    Length of approval: 12 months

    None explicitly stated in this document.

    The policy does not list additional non-coverage conditions beyond failure to meet the stated exception criteria (for example, insufficient trials or lack of prescriber justification would result in non-approval).

    Provider Requirements and Prior Authorization

    Prior Authorization

    Submit evidence that non‑formulary exception criteria are met

    Prior authorization requires submission of evidence that the non‑formulary exception criteria are met: either documentation of three failed or intolerant trials of formulary alternatives (including trial/failure of the generic equivalent when the requested product is a multi‑source brand with a formulary generic) OR a prescriber explanation why formulary alternatives are unsuitable.

    • If three formulary agents with a similar mechanism are not available, documentation of three medically acceptable formulary alternatives is required.
    • Length of approval: 12 months.
    Step Therapy

    Step therapy: try ≥3 formulary alternatives before exception

    The policy requires a step trial of at least three formulary alternatives prior to approval of a non‑formulary exception unless the prescriber documents why those alternatives are not appropriate.

    • Alternatives should have a similar mechanism of action when available; if not, three medically acceptable alternatives must be tried.

    Step Therapy Requirements

    StepRequirementDocumentation neededLength of approval
    1Trial of at least three formulary alternatives with a similar mechanism of action prior to non‑formulary exception approval; if three similar agents are not available on formulary, trial of three medically acceptable formulary alternativesDocumentation that the member tried and did not respond to or did not tolerate each of the three formulary alternatives. If the requested medication is a multi‑source brand and a generic equivalent is on formulary, documentation must show trial and failure of the generic as one of the three alternatives.12 months
    2Or: prescriber provides a clinical explanation why formulary alternatives would be ineffective or would cause adverse effectsWritten prescriber rationale explaining why formulary alternatives are not appropriate or would cause adverse effects12 months

    Definitions and Important Terms

    Multi-source brand
    DefinitionMulti-source brand: a brand drug with a generic equivalent; if the generic equivalent is covered on the formulary, the member must have tried and failed the generic as one of the three required formulary alternatives.
    Required trial countMust try at least three alternative formulary medications (similar mechanism of action preferred) before exception approval.
    When similar agents unavailableIf three medications with a similar mechanism are not on formulary, the member must try three medically acceptable formulary alternatives.
    Documentation implicationDocumentation must show trial and failure of the generic equivalent when the requested drug is a multi-source brand and the generic is on formulary.
    Related policy noteFailure to document these trials (including the generic for multi-source brands) risks denial for insufficient trials.

    Background

    This policy governs exceptions to the plan formulary for Medicare Part D members when a prescriber requests coverage for a non-formulary medication. It establishes minimum trial and documentation expectations to demonstrate medical necessity or intolerance to formulary alternatives, including a specific requirement for multi-source brand drugs: if a generic equivalent is on the formulary, the generic must be tried and failed as one of the three required alternatives. The standard length of approval for an approved exception is 12 months.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyNon-Formulary Exception Criteria for Approval
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Last ReviewJan 1, 2025
    Next Review DateJan 1, 2025
    Key ActionObtain prior authorization with documentation showing trial and failure or intolerance of at least three formulary alternatives (or prescriber justification why alternatives are unsuitable).
    SourceLink
    On This Page
    Non‑Formulary Exception Coverage CriteriaProvider Requirements and Prior AuthorizationStep Therapy RequirementsDefinitions and Important TermsBackground
  1. Trial and lack of response or intolerance must be documented for each alternative.
  2. Documentation Required

    Document trials and outcomes for ≥3 formulary alternatives

    Provide clinical documentation that the member tried and either did not respond to or did not tolerate at least three alternative formulary medications with a similar mechanism of action, or documentation explaining why formulary alternatives would be ineffective or cause adverse effects. If the requested drug is a multi‑source brand with a formululary generic, include trial and failure of the generic as one of the three alternatives.

    • Specify dates, doses, and reasons for discontinuation (nonresponse or intolerance) for each formulary alternative tried.
    • If similar‑mechanism agents aren’t on formulary, document three medically acceptable alternatives tried.
    Denial Risk

    Insufficient trials or missing documentation may lead to denial

    Failure to document that the member has tried at least three alternative formulary medications with a similar mechanism of action (or three medically acceptable alternatives when similar agents are not available), or failure to document trial and lack of response or intolerance, may result in denial of the non‑formulary exception request.

    • Include trial evidence (or prescriber justification) to avoid denial.
    • For multi‑source brands, lack of documented trial of the generic equivalent as one of the three alternatives risks denial.